Purple Biotech's NT219 Reaches Recommended Phase 2 Dose
Ticker: PPBT · Form: 6-K · Filed: Feb 1, 2024 · CIK: 1614744
Complexity: simple
Sentiment: bullish
Topics: drug-development, clinical-trials, biotech, milestone
TL;DR
**Purple Biotech hit a key milestone, NT219 is ready for Phase 2!**
AI Summary
Purple Biotech Ltd. announced on February 1, 2024, that it has successfully reached the recommended Phase 2 dose for its drug candidate, NT219. This significant milestone, detailed in a press release attached as Exhibit 99.1, means the company can now advance NT219 into the next stage of clinical trials, potentially bringing it closer to market. For investors, this progress in drug development is crucial as it de-risks the asset and could lead to increased valuation if Phase 2 trials are successful.
Why It Matters
Advancing NT219 to Phase 2 trials is a critical step in drug development, potentially increasing the drug's value and Purple Biotech's future revenue prospects if successful.
Risk Assessment
Risk Level: medium — While reaching Phase 2 is positive, drug development still carries significant risk, as many drugs fail in later stages.
Analyst Insight
A smart investor would monitor news regarding the initiation and progress of NT219's Phase 2 trials, as successful outcomes could significantly boost the stock.
Key Numbers
- 001-37643 — Commission File Number (Identifies Purple Biotech's registration with the SEC)
- 20240201 — Filing Date (The date the 6-K report was filed with the SEC)
Key Players & Entities
- Purple Biotech Ltd. (company) — the registrant issuing the 6-K filing
- NT219 (drug) — the drug candidate that reached its recommended Phase 2 dose
- February 1, 2024 (date) — the date the press release was issued and the 6-K was filed
- 001-37643 (number) — Purple Biotech's Commission File Number
Forward-Looking Statements
- Purple Biotech will initiate Phase 2 clinical trials for NT219 within the next 6-12 months. (Purple Biotech Ltd.) — high confidence, target: 2025-02-01
- The successful advancement of NT219 to Phase 2 will positively impact Purple Biotech's stock price. (Purple Biotech Ltd.) — medium confidence, target: 2024-08-01
FAQ
What is the primary purpose of Purple Biotech Ltd.'s 6-K filing on February 1, 2024?
The primary purpose of Purple Biotech Ltd.'s 6-K filing on February 1, 2024, is to report that the company issued a press release titled "Purple Biotech Reaches Recommended Phase 2 Dose for NT219," which is attached as Exhibit 99.1.
What is NT219, and what significant milestone did it achieve as reported in this filing?
NT219 is a drug candidate developed by Purple Biotech Ltd. The significant milestone achieved, as reported in the filing, is reaching its recommended Phase 2 dose, allowing it to advance to the next stage of clinical trials.
Which SEC forms are incorporating this 6-K filing by reference?
This 6-K filing, including all exhibits, is incorporated by reference into several of Purple Biotech's Registration Statements, specifically Form S-8 (file numbers 333-211478, 333-218538, 333-230584) and Form F-3 (file number 333-226195).
What is Purple Biotech Ltd.'s business address as stated in the filing?
Purple Biotech Ltd.'s business address is 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel.
What was Purple Biotech Ltd.'s former company name before its most recent change?
Before its most recent name change to Purple Biotech Ltd. on January 25, 2018, the company's former name was Kitov Pharma Ltd.
Filing Stats: 517 words · 2 min read · ~2 pages · Grade level 20 · Accepted 2024-02-01 07:40:11
Filing Documents
- ea192633-6k_purplebio.htm (6-K) — 13KB
- ea192633ex99-1_purplebio.htm (EX-99.1) — 14KB
- 0001213900-24-008736.txt ( ) — 28KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. February 1, 2024 PURPLE BIOTECH LTD. By: /s/ Lior Fhima Lior Fhima Chief Financial Officer 2